BTBP(SH:600161) Wanlian Securities·2024-10-28 09:00Investment Rating - The investment rating for the company is "Buy" [4][10]. Core Views - The company reported a revenue of 4.073 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 1.28%, while the net profit attributable to shareholders reached 1.052 billion yuan, up 18.52% year-on-year [1]. - The company has a leading position in the blood products industry, with a total of 102 plasma collection stations across 16 provinces, capturing approximately 20% of the domestic plasma collection volume [2]. - The company is actively advancing its new product development, focusing on high-concentration human immunoglobulin and recombinant coagulation factors, maintaining a leading position in the industry [3]. Financial Performance - For Q3 2024, the company achieved a revenue of 1.232 billion yuan, a decrease of 7.44% year-on-year, but an increase of 23.92% quarter-on-quarter. The net profit attributable to shareholders was 326 million yuan, up 1.57% year-on-year but down 20.46% quarter-on-quarter [1]. - The company's gross margin and net margin for the first three quarters of 2024 were 55.33% and 35.04%, respectively, showing increases of 5.72 percentage points and 5.01 percentage points year-on-year [5]. - The company has adjusted its profit forecast, expecting net profits of 1.237 billion yuan, 1.445 billion yuan, and 1.746 billion yuan for 2024, 2025, and 2026, respectively [6]. Market Position and Growth Potential - The company benefits from strong support from state-owned enterprises, enhancing its ability to expand plasma collection resources [2]. - The company is set to enhance its production capacity with three blood product production bases, each designed to have a capacity of 1,200 tons [2]. - The company is expected to maintain stable product demand in the blood products sector, which is characterized by high barriers to entry [6].